The Kentucky resident with AMD recently
gifted her home to FFB to raise awareness
about blinding conditions.
MY NAME IS DELORIS ADAMS. I have had age-related macular degeneration (AMD) for 19 years. When I was originally diagnosed, I
had never heard of it and had no idea that there were a
number of retinal diseases in the world impacting people.
AMD impacts my day-to-day life as I can no longer
do the things that I have been accustomed to doing. I
used to take my eyes for granted, but I realize now how
important it is to keep my eyes healthy.
I got involved with FFB because I wanted to bring
about more awareness and assist in funding research to
help others. People really need to take better care of their
eyes. If I had known what I know now, I believe things
might be better.
I was born the daughter of a coal miner and I did not
grow up with a lot of money, but I was fortunate enough
to get married and have a beautiful family. Last year in
June, I lost my husband and when the thought came to
me about the possibility of donating my Georgia home
to FFB, I contacted John Corneille, FFB’s director of gift
planning, to talk about it. John and I talked about my
idea, at length, involved my tax advisor and real estate
broker and, in the end, the gift was completed. I was
further motivated to donate my Georgia home to FFB
because of The Gordon and Llura Gund Family Chal-
lenge. When I learned that my gift would, indeed, be
matched dollar-for-dollar by Mr. Gund and his family,
I was ecstatic!
I hope that others will do the same and consider
donating to FFB. I hope that one day these conditions
will no longer exist and people can lead full, healthy lives
with crystal clear vision.
If you want to learn more about how a gift of real
estate can benefit FFB’s research, please contact John
Corneille, FFB’s director of gift planning, at jcorneille@
“I hope that others will do the same and consider
donating to FFB,” says Deloris Adams, center.
From Bad to Good
The National Eye Institute, one of
the United States’ National Institutes of Health, recently launched
a first-time-ever clinical trial for a
gene therapy targeting X-linked
retinoschisis, otherwise known
as XLRS. The vision-stealing condition affects males exclusively,
as many 140,000 worldwide. The
treatment replaces defective copies
of the RS1 gene with healthy ones.
For more information:
Two Out of Three
This past year’s been a big one
for choroideremia patients. In
2014, a British research team reported positive early results for a
gene therapy it’s testing in a clinical
trial, and a Canadian team is preparing to launch its own trial. In the
meantime, Spark Therapeutics, a
company, launched a clinical trial
in January. Read more about it at
So Far, So Good
It’s early yet, but results from a
clinical trial involving the use of
stem cells to treat multiple retinal
diseases bodes well for a future
expansion of the study. Researchers funded, in part, by FFB took
bone-marrow stem cells from each
patient’s hip, rejiggered them to
become retinal cells, then injected
those cells into the patient’s vitreous.
There were no harmful effects and
moderately improved vision. For
Check out of these summaries of recent retinal-research
advancements, then go online to get the full stories.